Daiken Biomedical Co., Ltd.
Daiken Biomedical Co., Ltd. engages in the research and development of healthy food products. The company is based in Taipei, Taiwan. Daiken Biomedical Co., Ltd. is a subsidiary of Sunfun Info Co., Ltd.
Daiken Biomedical Co., Ltd. (7780) - Total Assets
Latest total assets as of September 2025: NT$5.65 Billion TWD
Based on the latest financial reports, Daiken Biomedical Co., Ltd. (7780) holds total assets worth NT$5.65 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Daiken Biomedical Co., Ltd. - Total Assets Trend (2022–2024)
This chart illustrates how Daiken Biomedical Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Daiken Biomedical Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Daiken Biomedical Co., Ltd.'s total assets of NT$5.65 Billion consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 74.1% |
| Accounts Receivable | NT$93.50 Million | 6.1% |
| Inventory | NT$245.71 Million | 16.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Daiken Biomedical Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daiken Biomedical Co., Ltd.'s current assets represent 98.3% of total assets in 2024, a decrease from 98.8% in 2022.
- Cash Position: Cash and equivalents constituted 74.1% of total assets in 2024, up from 46.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is inventory at 16.0% of total assets.
Daiken Biomedical Co., Ltd. Competitors by Total Assets
Key competitors of Daiken Biomedical Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩123.42 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
China | CN¥1.25 Billion |
|
Daehan Flour Mills Co Ltd
KO:001130
|
Korea | ₩1.61 Trillion |
Daiken Biomedical Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Daiken Biomedical Co., Ltd. generates 0.89x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Daiken Biomedical Co., Ltd. generates $6.93 in net profit.
Daiken Biomedical Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.43 | 4.18 | 4.18 |
| Quick Ratio | 18.04 | 3.41 | 3.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$5.32 Billion | NT$ 1.29 Billion | NT$ 1.29 Billion |
Daiken Biomedical Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Daiken Biomedical Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.99 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 106.4% |
| Total Assets | NT$1.54 Billion |
| Market Capitalization | $134.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daiken Biomedical Co., Ltd.'s assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Daiken Biomedical Co., Ltd.'s assets grew by 106.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Daiken Biomedical Co., Ltd. (2022–2024)
The table below shows the annual total assets of Daiken Biomedical Co., Ltd. from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.54 Billion | +106.37% |
| 2023-12-31 | NT$745.17 Million | +40.55% |
| 2022-12-31 | NT$530.16 Million | -- |